All News
Filter News
Found 68 articles
-
Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients
5/27/2020
Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced a health update for two critically ill COVID-19 patients who were treated at Landmark Hospital in Athens, GA with the Company’s Organicell Flow product.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 19, 2020.
-
FDA Approves Two Emergency INDs to Administer Organicell Flow for COVID-19
5/19/2020
Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that on May 11, 2020, the U.S. Food and Drug Administration authorized two Emergency Compassionate Use Investigational New Drug applications, each for a single patient severely ill from COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.
-
Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19
5/5/2020
Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Organicell Flow, for patients diagnosed with moderate to severe acute respiratory syndrome (SARS) due to COVID-19 infection. This trial will be the first ra
-
Organicell Regenerative Medicine Inc. Provides Update On Operations and Financial Reporting Status
1/21/2020
Organicell Regenerative Medicine Inc. (OTCPK:BPSR) (the “Company”) is pleased to provide shareholders and the investment community with an update on operations since its filing on November 1, 2018 of the Company’s Annual Report on Form filing of Form 10-K for the year ended October 31, 2017, as well as the status of becoming fully compliant with SEC reporting obligations.
-
Organicell Welcomes Dr. George C. Shapiro To The Medical Advisory Board
2/25/2019
Biotech Products Services and Research, Inc. operating as Organicell Regenerative Medicine Inc. (OTC: BPSR), today announced the appointment of George C. Shapiro, M.D. F.A.C.C. to its medical advisory board.
-
Organicell Regenerative Medicine Inc., Biotech Products Services and Research, Inc. Update for Shareholders
1/30/2019
Biotech Products Services and Research, Inc. operating as Organicell Regenerative Medicine Inc. (OTC: BPSR), today is providing its shareholders with an update on the Company's progress.